Our research into different forms of cancer

Need to know more about research we're doing into a specific type of cancer affecting you, a friend or a loved one? We can tell you about how we've changed diagnosis and treatment for people with many different types of cancer and provide information about our latest discoveries.

Choose a type of cancer

We’re leading research across all major forms of cancer. Find out some of our top breakthroughs and what we're currently researching.

Clinical Trials at ICR-CTSU

Our Clinical Trials & Statistics Unit (ICR-CTSU) regularly recruits across various cancer types to test drugs, screening methods and more
More about out trials
The Rudy A Menon Foundation

Family Charity Partners

The Rudy A Menon Foundation funds brain cancer research including Gliomatosis Cerebri.

Read more

Make a donation today

A £10 donation each month can supply our team with equipment to undertake a number of tests/experiments
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

A £10 donation each month can supply our team with equipment to undertake a number of tests/experiments
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Closed: Triple Negative Breast cancer control of the immune tumour microenvironment in metastasis

Primary supervisor: Professor Victoria Sanz-Moreno Primary site: Chelsea Funded by UKRI Closed: Triple Negative Breast cancer control of the immune tumour microenvironment in metastasis

See full project details

Our very latest cancer discoveries & news

Red, yellow and blue microscope image of immunofluorescence staining showing extension of prostatic adenocarcinoma into the bladder wall
New drug hope for prostate cancer patients

10/01/25

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.
See full story
Left: Plates showing the impact of olaparib on BRCA cancer cells and minimal impact of on healthy cells. (Right) Lynparza, olaparib's brand name, drug packaging. Photo credit: Science Museum Group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
See full story
Scientists in the lab pipetting
Supporting scientists to choose the best chemical probes

02/01/25

A ‘TripAdvisor-style’ website that helps scientists choose the best small-molecule tools for their experiments has been greatly expanded to include expert reviews of hundreds of chemical probes that can be used to increase the robustness of fundamental and applied research and help develop an arsenal of new cancer drugs.
See full story
Sentinal leadership team Georgia Mitsi, Chris Bakal, Matt de Vries
Precision oncology company Sentinal4D completes pre-seed funding round and launches to the public

20/12/24

Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed of its first round of funding and appointed its foundational leadership team.
See full story